B16F10-LUC-OVA Cell Line

B16F10-LUC-OVA cell line is engineered to precisely recapitulate the complexity of the tumor microenvironment, providing a robust and reliable model for immuno-oncology studies. Featuring stable OVA antigen expression in B16F10, it simulates tumor-specific antigen presentation, enabling accurate and reproducible evaluation of therapeutic efficacy for vaccines, T-cell therapies, and immune checkpoint inhibitors.
Designed for efficiency, this B16F10-LUC-OVA combines dual reporters in a single system: Luciferase (Luc) for sensitive in vivo imaging and real-time tumor tracking, and OVA as a well-defined immune antigen for potent T-cell activation. This all-in-one design streamlines experimental workflows, reduces model variability, and accelerates your research from in vitro validation to in vivo analysis.